Intensity Therapeutics Stock Forum

$Intensity Therapeutics (INTS.US)$
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)
Thursday, 12th December at 8:00 am
Enrollment is ongoing and seven sites in Switzerland have been ...

$Intensity Therapeutics (INTS.US)$ Reuters· just
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

$Intensity Therapeutics (INTS.US)$
08/11/2024 - 21:01
SHELTON, Conn., Nov. 8, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumorally injected cancer therapies inte...

$Intensity Therapeutics (INTS.US)$
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)
Testing the efficacy and safety of Intensity's lead drug candidate, INT230-6, when combined with Standard-of-Care versus Standard-of-Care alone
The endpoint is the change in pathological complete response rates
SHELTON, Conn. and BE...

$China Pharma (CPHI.US)$ $Bright Minds Biosciences (DRUG.US)$ $Lantern Pharma (LTRN.US)$ $Cytosorbents (CTSO.US)$ $Intensity Therapeutics (INTS.US)$ $Multi Ways (MWG.US)$ $Salarius Pharmaceuticals (SLRX.US)$ $X3 Holdings (XTKG.US)$ $Protagenic Therapeutics (PTIX.US)$ $GRI Bio (GRI.US)$ $Paranovus Entertainment Technology (PAVS.US)$ $VSee Health (VSEE.US)$
📊⚡️📊

$Intensity Therapeutics (INTS.US)$
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
Intensity Therapeutics (Nasdaq: INTS) has announced the dosing of the first U.S. patient in its global Phase 3 study (INVINCIBLE-3) for metastatic soft tissue sarcoma using its lead product candidate, INT230-6, as a monotherapy. This trial will compare INT230-6 against standard-of-care chemotherapy in second and ...

$Intensity Therapeutics (INTS.US)$ Benzinga· 5 mins ago
Intensity Therapeutics Signs Collaboration Agreement With The Swiss Group For Clinical Cancer Research SAKK To Conduct Phase 2 Breast Cancer Trial In Europe For INT230-6

$Intensity Therapeutics (INTS.US)$
NEWS
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate
Positive
The collaboration agreement between Intensity Therapeutics, Inc. and SAKK for the Phase 2 clinical trial demonstrates the company's commitment to advancing its lead drug candidate, INT230-6.
INT230-6 has s...